Vacciguard Novel Vaccines

Vacciguard novel vaccines

 

The main challenge faced by the healthcare system is a high recurrence rate
following treatment by the existing standard therapies
VacciGuard's Lung Cancer Vaccines Print E-mail
VacciGuard's lung cancer vaccine consists of VacciGuard's proprietary carrier peptide conjugated with a polysaccharide antigen.

The polysaccharide antigen, used for generating the vaccine is expressed in malignancies of neuroectoderm origin, such as small cell lung cancer (SCLC), non-small cell lung carcinomas (NSCLC), multiple myelonoma (MM), neuroblastoma, human breast carcinoma and leukemia. In SCLC, NSCLC and MM the expression of the selected antigen is correlated with tumor progression.

The selected polysaccharide antigen is also expressed in the embryonic stage, but does not persist into adulthood. In adults the selected antigen is not detected in normal tissues, but is abundant in cancer cells.

So far, attempts to generate IgG antibodies against this target antigen have not been successful due to the poor immunogenicity of the antigen.

VacciGuard has shown in animal studies that conjugation of the selected antigen with peptides derived from the HSP-60 protein yields long lasting IgG antibodies and therefore may serve as an effective vaccine.

Back